Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature
Objectives. To analyze and summarize the effect of SSA treatment on EAS due to p-NETs (EAS-p-NETs). Methods. Thirteen patients with EAS-p-NETs treated with SSAs at our center or described in the literature were included in this study. Clinical characteristics, laboratory data, imaging studies, histo...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2022/6283706 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548600114053120 |
|---|---|
| author | Da Zhang Lin Lu Hui-Juan Zhu Yu Xiao Xian-Lin Han Shun-Da Du Hua-Dan Xue Qing-Xing Liu Zhao-Hui Zhu Ming-Ming Hu Xiao Zhai Xiao-Ping Xing Zhao-Lin Lu |
| author_facet | Da Zhang Lin Lu Hui-Juan Zhu Yu Xiao Xian-Lin Han Shun-Da Du Hua-Dan Xue Qing-Xing Liu Zhao-Hui Zhu Ming-Ming Hu Xiao Zhai Xiao-Ping Xing Zhao-Lin Lu |
| author_sort | Da Zhang |
| collection | DOAJ |
| description | Objectives. To analyze and summarize the effect of SSA treatment on EAS due to p-NETs (EAS-p-NETs). Methods. Thirteen patients with EAS-p-NETs treated with SSAs at our center or described in the literature were included in this study. Clinical characteristics, laboratory data, imaging studies, histopathologic results, the effect of SSA treatment, and the prognosis of these EAS-p-NET patients were evaluated. Results. Four males and 9 females with an average age of 42.9 years were included in the study. The mean duration of follow-up was 38.8 ± 28.2 months. As one of the combined treatment measures, SSAs controlled the levels of ACTH and cortisol in 9 of the 13 patients (69.2%). Partial response was observed in 3 patients (23.1%), stable disease in 2 patients (15.4%), and progressive disease in 6 patients (46.2%). The median time to tumor progression was 24 months, and the median overall survival was 61 months. The side effects of SSA treatment included temporary mild abdominal pain, diarrhea, gallstones, and cholecystitis. Conclusions. As a supplemental therapy, SSA treatment led to clinical and biochemical improvement with a good safety profile in patients exhibiting EAS-p-NET with metastasis. However, tumor progression was inhibited by SSA treatment in only a few patients. Combined with other treatments, SSAs may improve the prognosis of patients with EAS-p-NETs. |
| format | Article |
| id | doaj-art-4af07185acd04753a2f2bd4e3874a349 |
| institution | Kabale University |
| issn | 1687-8345 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-4af07185acd04753a2f2bd4e3874a3492025-02-03T06:13:35ZengWileyInternational Journal of Endocrinology1687-83452022-01-01202210.1155/2022/6283706Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the LiteratureDa Zhang0Lin Lu1Hui-Juan Zhu2Yu Xiao3Xian-Lin Han4Shun-Da Du5Hua-Dan Xue6Qing-Xing Liu7Zhao-Hui Zhu8Ming-Ming Hu9Xiao Zhai10Xiao-Ping Xing11Zhao-Lin Lu12Department of EndocrinologyDepartment of EndocrinologyDepartment of EndocrinologyDepartment of PathologyDepartment of General SurgeryDepartment of General SurgeryDepartment of RadiologyDepartment of Nuclear MedicineDepartment of Nuclear MedicineDepartment of EndocrinologyDepartment of EndocrinologyDepartment of EndocrinologyDepartment of EndocrinologyObjectives. To analyze and summarize the effect of SSA treatment on EAS due to p-NETs (EAS-p-NETs). Methods. Thirteen patients with EAS-p-NETs treated with SSAs at our center or described in the literature were included in this study. Clinical characteristics, laboratory data, imaging studies, histopathologic results, the effect of SSA treatment, and the prognosis of these EAS-p-NET patients were evaluated. Results. Four males and 9 females with an average age of 42.9 years were included in the study. The mean duration of follow-up was 38.8 ± 28.2 months. As one of the combined treatment measures, SSAs controlled the levels of ACTH and cortisol in 9 of the 13 patients (69.2%). Partial response was observed in 3 patients (23.1%), stable disease in 2 patients (15.4%), and progressive disease in 6 patients (46.2%). The median time to tumor progression was 24 months, and the median overall survival was 61 months. The side effects of SSA treatment included temporary mild abdominal pain, diarrhea, gallstones, and cholecystitis. Conclusions. As a supplemental therapy, SSA treatment led to clinical and biochemical improvement with a good safety profile in patients exhibiting EAS-p-NET with metastasis. However, tumor progression was inhibited by SSA treatment in only a few patients. Combined with other treatments, SSAs may improve the prognosis of patients with EAS-p-NETs.http://dx.doi.org/10.1155/2022/6283706 |
| spellingShingle | Da Zhang Lin Lu Hui-Juan Zhu Yu Xiao Xian-Lin Han Shun-Da Du Hua-Dan Xue Qing-Xing Liu Zhao-Hui Zhu Ming-Ming Hu Xiao Zhai Xiao-Ping Xing Zhao-Lin Lu Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature International Journal of Endocrinology |
| title | Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature |
| title_full | Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature |
| title_fullStr | Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature |
| title_full_unstemmed | Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature |
| title_short | Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature |
| title_sort | somatostatin treatment for ectopic acth syndrome due to pancreatic neuroendocrine tumors review of the literature |
| url | http://dx.doi.org/10.1155/2022/6283706 |
| work_keys_str_mv | AT dazhang somatostatintreatmentforectopicacthsyndromeduetopancreaticneuroendocrinetumorsreviewoftheliterature AT linlu somatostatintreatmentforectopicacthsyndromeduetopancreaticneuroendocrinetumorsreviewoftheliterature AT huijuanzhu somatostatintreatmentforectopicacthsyndromeduetopancreaticneuroendocrinetumorsreviewoftheliterature AT yuxiao somatostatintreatmentforectopicacthsyndromeduetopancreaticneuroendocrinetumorsreviewoftheliterature AT xianlinhan somatostatintreatmentforectopicacthsyndromeduetopancreaticneuroendocrinetumorsreviewoftheliterature AT shundadu somatostatintreatmentforectopicacthsyndromeduetopancreaticneuroendocrinetumorsreviewoftheliterature AT huadanxue somatostatintreatmentforectopicacthsyndromeduetopancreaticneuroendocrinetumorsreviewoftheliterature AT qingxingliu somatostatintreatmentforectopicacthsyndromeduetopancreaticneuroendocrinetumorsreviewoftheliterature AT zhaohuizhu somatostatintreatmentforectopicacthsyndromeduetopancreaticneuroendocrinetumorsreviewoftheliterature AT mingminghu somatostatintreatmentforectopicacthsyndromeduetopancreaticneuroendocrinetumorsreviewoftheliterature AT xiaozhai somatostatintreatmentforectopicacthsyndromeduetopancreaticneuroendocrinetumorsreviewoftheliterature AT xiaopingxing somatostatintreatmentforectopicacthsyndromeduetopancreaticneuroendocrinetumorsreviewoftheliterature AT zhaolinlu somatostatintreatmentforectopicacthsyndromeduetopancreaticneuroendocrinetumorsreviewoftheliterature |